These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 32814461

  • 1. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y, Tummala R.
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [Abstract] [Full Text] [Related]

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF, Anderson CW.
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [Abstract] [Full Text] [Related]

  • 3. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S, CD1013 Study Investigators.
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [Abstract] [Full Text] [Related]

  • 4. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R, TULIP-2 Trial Investigators.
    N Engl J Med; 2020 Jan 16; 382(3):211-221. PubMed ID: 31851795
    [Abstract] [Full Text] [Related]

  • 5. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.
    Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, Morand EF.
    Lupus Sci Med; 2021 Feb 16; 8(1):. PubMed ID: 33597205
    [Abstract] [Full Text] [Related]

  • 6. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R, Scher F, Sagez F, Chasset F, Arnaud L.
    Drug Des Devel Ther; 2019 Feb 16; 13():1535-1543. PubMed ID: 31190735
    [Abstract] [Full Text] [Related]

  • 7. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
    Tanaka Y, Atsumi T, Okada M, Miyamura T, Ishii T, Nishiyama S, Matsumura R, Hayashi N, Abreu G, Tummala R, Morand EF, Takeuchi T.
    Mod Rheumatol; 2023 Jan 03; 33(1):134-144. PubMed ID: 35134970
    [Abstract] [Full Text] [Related]

  • 8. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
    Bruce IN, van Vollenhoven RF, Psachoulia K, Lindholm C, Maho E, Tummala R.
    Lupus Sci Med; 2023 Jan 03; 10(1):. PubMed ID: 36639192
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.
    Liu Z, Cheng R, Liu Y.
    Front Immunol; 2022 Jan 03; 13():996662. PubMed ID: 36211347
    [Abstract] [Full Text] [Related]

  • 10. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus.
    Ahmed AA, Osman N, Furie R.
    Expert Rev Clin Immunol; 2022 Nov 03; 18(11):1095-1106. PubMed ID: 36083692
    [Abstract] [Full Text] [Related]

  • 11. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.
    Anderson E, Furie R.
    Immunotherapy; 2020 Apr 03; 12(5):275-286. PubMed ID: 32237942
    [Abstract] [Full Text] [Related]

  • 12. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF, Abreu G, Furie RA, Golder V, Tummala R.
    Ann Rheum Dis; 2023 May 03; 82(5):639-645. PubMed ID: 36690388
    [Abstract] [Full Text] [Related]

  • 13. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
    Bruce IN, Furie RA, Morand EF, Manzi S, Tanaka Y, Kalunian KC, Merrill JT, Puzio P, Maho E, Kleoudis C, Albulescu M, Hultquist M, Tummala R.
    Ann Rheum Dis; 2022 Jul 03; 81(7):962-969. PubMed ID: 35580976
    [Abstract] [Full Text] [Related]

  • 14. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
    Chia YL, Tummala R, Mai TH, Rouse T, Streicher K, White WI, Morand EF, Furie RA.
    J Clin Pharmacol; 2022 Sep 03; 62(9):1094-1105. PubMed ID: 35352835
    [Abstract] [Full Text] [Related]

  • 15. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R.
    Ann Rheum Dis; 2022 Jul 03; 81(7):951-961. PubMed ID: 35338035
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
    Tanaka Y, Takeuchi T, Okada M, Ishii T, Nakajima H, Kawai S, Nagashima T, Hayashi N, Wang L, Tummala R.
    Mod Rheumatol; 2020 Jan 03; 30(1):101-108. PubMed ID: 30793642
    [Abstract] [Full Text] [Related]

  • 17. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
    Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF.
    Rheumatology (Oxford); 2022 May 05; 61(5):1900-1910. PubMed ID: 34528084
    [Abstract] [Full Text] [Related]

  • 18. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
    Furie R, Morand EF, Askanase AD, Vital EM, Merrill JT, Kalyani RN, Abreu G, Pineda L, Tummala R.
    Lupus; 2021 Jul 05; 30(8):1254-1263. PubMed ID: 33977796
    [Abstract] [Full Text] [Related]

  • 19. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.
    Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R.
    Ann Rheum Dis; 2018 May 05; 77(5):706-713. PubMed ID: 29420200
    [Abstract] [Full Text] [Related]

  • 20. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
    Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, Knagenhjelm J, Schwetje E, Chia YL, Tummala R, Lindholm C.
    Ann Rheum Dis; 2022 Apr 05; 81(4):496-506. PubMed ID: 35144924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.